Yale Urology’s commitment to research continues to grow with now three associate research scientists as part of the oncology section.
Dawoon Esther Jung, PhD, came to us from the Institute of Gastroenterology at Yonsei University in Seoul, South Korea, where she was an associate research professor. Yonsei was also where she earned her PhD in cancer biology and a master’s in pharmacology.
Jung’s latest research focuses on tumor microenvironments, chemo-resistant genes, and targeted therapies for tumor-related cancer stem cells. She is currently working with Isaac Kim on the mechanisms of prostate cancer resistance to therapy and transdifferentiation.
Xiaoling Li [pronounced Shyao-ling Lee], PhD, joins us from UT Southwestern Medical Center, where she completed a postdoctoral fellowship in the Department of Molecular Biology.
Li earned her PhD in cell biology from Zhejiang University in Hangzhou, China.
She has been a reviewer for several journals, including BioMed Research International, Frontiers in Endocrinology, and Frontiers in Oncology, and has received several awards, including the Early Investigator Research Award from the U.S. Department of Defense.
She is part of Ping Mu’s lab team.
Yaru Xu [pronounced Ya-roo Shu], PhD, also comes to us from UT Southwestern. She obtained her PhD from Zhejiang U.
Her research focus, also in the Mu Lab, surrounds long non-coding RNAs [lncRNAs] and their roles in regulating therapy resistance in prostate cancer and other urological diseases. Her goal is to unravel the complex biology of novel RNA classes and deepen our understanding of how lncRNAs influence health and disease.
She has been the first author of nearly a dozen peer-reviewed publications.